Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera

The FDA has approved Takeda’s Mimrylo (rusfertide) for polyc | The FDA has approved Takeda’s Mimrylo (rusfertide) for polycythemia vera, introducing a new mechanism to the nonmalignant rare blood cancer and handing CEO…